{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T17:41:13Z","timestamp":1791222073241,"version":"4.1.0"},"reference-count":71,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:00:00Z","timestamp":1771027200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Dupilumab is a human monoclonal antibody that targets both IL-4 and IL-13 signaling. Eosinophilia has been reported as a potential adverse event in treated patients in randomized controlled trials and 12-month real-life studies. This real-life, 24-month prospective study investigated the prevalence of eosinophilia, its consequences, and the effectiveness of dupilumab in a cohort of patients with severe asthma, chronic rhinosinusitis with nasal polyps, and atopic dermatitis. Methods: A total of 66 adult patients treated with dupilumab were included in this study. ACT, SNOT-22, and Smell-VAS, EASI, and absolute blood eosinophil count (AEC) were assessed according to the type of diagnosis at baseline (T0), after 6 (T6), 12 (T12), 18 (T18), and 24 (T24) months post-dupilumab initiation. Results: All patients experienced significant improvement in both symptoms and disease control following dupilumab treatment. A total of 27 out of 66 (40.9%) patients developed eosinophilia within six months of treatment (AEC T6 mean \u00b1 SD 0.67 \u00b1 0.68 109\/L). Eosinophilia was generally mild and lasted on average for six months (AEC T12 mean \u00b1 SD 0.66 \u00b1 0.65 109\/L) with AEC normalization after 18 months of treatment (AEC T18 mean \u00b1 SD 0.58 \u00b1 0.48 109\/L). Ten patients (15.15%) developed hypereosinophilia, but no symptoms or signs of eosinophilic-related organ damage have been observed, with no need for dupilumab discontinuation. Conclusions: Dupilumab-related eosinophilia was common, generally mild, and transient, whereas persistent hypereosinophilia occurred in a small group of patients in the absence of symptoms or signs of eosinophilic damage.<\/jats:p>","DOI":"10.3390\/jcm15041525","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T08:38:39Z","timestamp":1771231119000},"page":"1525","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Dupilumab-Related Hypereosinophilia in Patients Treated for Type 2 Diseases: Evidence from a 24-Month Prospective Real-Life Study"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7599-5426","authenticated-orcid":false,"given":"Ilaria","family":"Mormile","sequence":"first","affiliation":[{"name":"Department of Translational Medical Sciences, Federico II University, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9308-2508","authenticated-orcid":false,"given":"Daniele","family":"La Prova","sequence":"additional","affiliation":[{"name":"Post-Graduate Program in Clinical Immunology and Allergy, University of Naples Federico II, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7237-2641","authenticated-orcid":false,"given":"Paolo","family":"Pezzella","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Reproductive and Odontostomatological Sciences-ENT Section, University of Naples Federico II, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliano","family":"Di Caprio","sequence":"additional","affiliation":[{"name":"Post-Graduate Program in Clinical Immunology and Allergy, University of Naples Federico II, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0347-2540","authenticated-orcid":false,"given":"Amato","family":"de Paulis","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences, Federico II University, 80131 Naples, Italy"},{"name":"Center for Basic and Clinical Immunology Research (CISI), University of Naples Federico II, 80131 Naples, Italy"},{"name":"WAO Center of Excellence, 80131 Naples, Italy"},{"name":"Division of Internal Medicine and Clinical Immunology, Department of Internal Medicine and Clinical Complexity, University of Naples Federico II, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7389-2033","authenticated-orcid":false,"given":"Elena","family":"Cantone","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Health and Nutrition Sciences, University of Calabria, 87036 Rende, Italy"},{"name":"Otolaryngology Unit, Annunziata Hospital, 87100 Cosenza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3692-1384","authenticated-orcid":false,"given":"Aikaterini","family":"Detoraki","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine and Clinical Immunology, Department of Internal Medicine and Clinical Complexity, University of Naples Federico II, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s12016-022-08934-0","article-title":"Dupilumab-Associated Adverse Events During Treatment of Allergic Diseases","volume":"62","author":"Kychygina","year":"2022","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1016\/j.jaip.2022.05.019","article-title":"Effect of Dupilumab on Blood Eosinophil Counts in Patients with Asthma, Chronic Rhinosinusitis with Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis","volume":"10","author":"Wechsler","year":"2022","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1111\/all.15844","article-title":"Dupilumab-induced eosinophilia in patients with diffuse type 2 chronic rhinosinusitis","volume":"78","author":"Ryser","year":"2023","journal-title":"Allergy"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"165","DOI":"10.18176\/jiaci.0823","article-title":"Eosinophilia Induced by Blocking the IL-4\/IL-13 Pathway: Potential Mechanisms and Clinical Outcomes","volume":"32","author":"Olaguibel","year":"2022","journal-title":"J. Investig. Allergol. Clin. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1080\/17476348.2022.2090342","article-title":"Dupilumab-induced hypereosinophilia: Review of the literature and algorithm proposal for clinical management","volume":"16","author":"Caminati","year":"2022","journal-title":"Expert. Rev. Respir. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1001\/jamadermatol.2019.3617","article-title":"Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients with Atopic Dermatitis: A Randomized Clinical Trial","volume":"156","author":"Worm","year":"2020","journal-title":"JAMA Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Ferrucci, S., Casazza, G., Angileri, L., Tavecchio, S., Germiniasi, F., Berti, E., Marzano, A.V., and Genovese, G. (2020). Clinical Response and Quality of Life in Patients with Severe Atopic Dermatitis Treated with Dupilumab: A Single-Center Real-Life Experience. J. Clin. Med., 9.","DOI":"10.3390\/jcm9030791"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.jaip.2025.01.040","article-title":"Profiling Blood Hypereosinophilia in Patients on Dupilumab Treatment for Respiratory Conditions: A Real-Life Snapshot","volume":"13","author":"Caminati","year":"2025","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_10","first-page":"482","article-title":"Dupilumab-Induced Blood Eosinophilia in Patients with Chronic Rhinosinusitis with Nasal Polyps: Temporal Trends and Correlation with Adverse Events","volume":"14","author":"Montuori","year":"2025","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"575","DOI":"10.2147\/JAA.S312123","article-title":"Real-World Experience with Dupilumab in Severe Asthma: One-Year Data from an Italian Named Patient Program","volume":"14","author":"Campisi","year":"2021","journal-title":"J. Asthma Allergy"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/cea.13614","article-title":"Effectiveness and safety of dupilumab for the treatment of severe asthma in a real-life French multi-centre adult cohort","volume":"50","author":"Dupin","year":"2020","journal-title":"Clin. Exp. Allergy"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s12016-024-09020-3","article-title":"Clinical and Pathophysiological Tangles Between Allergy and Autoimmunity: Deconstructing an Old Dichotomic Paradigm","volume":"68","author":"Ramirez","year":"2025","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Mormile, M., Mormile, I., Fuschillo, S., Rossi, F.W., Lamagna, L., Ambrosino, P., de Paulis, A., and Maniscalco, M. (2023). Eosinophilic Airway Diseases: From Pathophysiological Mechanisms to Clinical Practice. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24087254"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1159\/000101412","article-title":"Differential regulation of chemokine expression by Th1 and Th2 cytokines and mechanisms of eotaxin\/CCL-11 expression in human airway smooth muscle cells","volume":"143","author":"Odaka","year":"2007","journal-title":"Int. Arch. Allergy Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Maniscalco, M., Fuschillo, S., Mormile, I., Detoraki, A., Sarnelli, G., Paulis, A., Spadaro, G., Cantone, E., and PATH-2 Task Force (2023). Exhaled Nitric Oxide as Biomarker of Type 2 Diseases. Cells, 12.","DOI":"10.3390\/cells12212518"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1111\/all.16610","article-title":"Dupilumab and Blood Eosinophilia: A Disease-Specific Phenomenon?","volume":"80","author":"Portacci","year":"2025","journal-title":"Allergy"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Zhou, X., Yang, G., Zeng, X., Wang, L., Xiang, J., Zhao, J., Chen, X., and Zhang, L. (2023). Dupilumab and the potential risk of eosinophilic pneumonia: Case report, literature review, and FAERS database analysis. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1277734"},{"key":"ref_19","first-page":"386","article-title":"Eosinophilic complications during dupilumab therapy for type 2 diseases: A systematic review","volume":"63","author":"Lazzeroni","year":"2025","journal-title":"Rhinology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1136\/ard-2023-224756","article-title":"Dupilumab for relapsing or refractory sinonasal and\/or asthma manifestations in eosinophilic granulomatosis with polyangiitis: A European retrospective study","volume":"82","author":"Molina","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/all.15544","article-title":"Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes","volume":"78","author":"Valent","year":"2023","journal-title":"Allergy"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/j.jaip.2022.03.034","article-title":"Clinical Profile and Treatment in Hypereosinophilic Syndrome Variants: A Pragmatic Review","volume":"10","author":"Requena","year":"2022","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Caminati, M., Brussino, L., Carlucci, M., Carlucci, P., Carpagnano, L.F., Caruso, C., Cosmi, L., D\u2019Amore, S., Del Giacco, S., and Detoraki, A. (2024). Managing Patients with Hypereosinophilic Syndrome: A Statement from the Italian Society of Allergy, Asthma, and Clinical Immunology (SIAAIC). Cells, 13.","DOI":"10.3390\/cells13141180"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Lin, T.Y., Wang, C.Y., Wang, F.Y., Kang, E.Y., and Hwang, Y.S. (2023). Association between Dupilumab and Conjunctivitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15041031"},{"key":"ref_25","first-page":"202","article-title":"Hypereosinophilia during dupilumab treatment in patients with chronic rhinosinusitis with nasal polyps","volume":"62","author":"Kemp","year":"2024","journal-title":"Rhinology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1111\/all.14964","article-title":"Eosinophilic pleural effusion and stroke with cutaneous vasculitis: Two cases of dupilumab-induced hypereosinophilia","volume":"76","author":"Lommatzsch","year":"2021","journal-title":"Allergy"},{"key":"ref_27","first-page":"100821","article-title":"Eosinophilic vasculitis associated with persistent dupilumab-induced hypereosinophilia in severe asthma","volume":"79","author":"Descamps","year":"2021","journal-title":"Respir. Med. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4477","DOI":"10.1016\/j.jaip.2021.07.049","article-title":"Hypereosinophilia with systemic manifestations under dupilumab and possibility of dual benralizumab and dupilumab therapy in patients with asthma and CRSwNP","volume":"9","author":"Briegel","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12348-020-00234-y","article-title":"Serum IgE reduction and paradoxical eosinophilia associated with allergic conjunctivitis after dupilumab therapy","volume":"11","author":"Kimura","year":"2021","journal-title":"J. Ophthalmic Inflamm. Infect."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1016\/j.jaip.2021.02.042","article-title":"Complications of switching from anti-IL-5 or anti-IL-5R to dupilumab in corticosteroid-dependent severe asthma","volume":"9","author":"Eger","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrd4624","article-title":"Targeting key proximal drivers of type 2 inflammation in disease","volume":"15","author":"Gandhi","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(16)30307-5","article-title":"Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting beta2 agonist: A randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial","volume":"388","author":"Wenzel","year":"2016","journal-title":"Lancet"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000504847","article-title":"The Cellular Functions of Eosinophils: Collegium Internationale Allergologicum (CIA) Update 2020","volume":"181","author":"Simon","year":"2020","journal-title":"Int. Arch. Allergy Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1182\/blood-2014-11-551614","article-title":"How I treat hypereosinophilic syndromes","volume":"126","author":"Klion","year":"2015","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"D\u2019Aiuto, V., Mormile, I., Granata, F., Romano, A., Della Casa, F., D\u2019Onofrio, C., Marzio, V., Mignogna, G., Califano, L., and de Paulis, A. (2024). Eosinophilic Patterns in Patients with Seasonal Allergy Affected by Bronchial Asthma and Rhinitis\/Rhinosinusitis: Efficacy of Benralizumab in Patients with the Persistent Pattern. J. Clin. Med., 13.","DOI":"10.3390\/jcm13030754"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mcna.2019.08.005","article-title":"Approach to Patients with Eosinophilia","volume":"104","author":"Kuang","year":"2020","journal-title":"Med. Clin. North Am."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13023-023-02696-4","article-title":"French guidelines for the etiological workup of eosinophilia and the management of hypereosinophilic syndromes","volume":"18","author":"Groh","year":"2023","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Nicola, S., Caminati, M., Borrelli, R., Lo Sardo, L., Corradi, F., Badiu, I., Vacca, A., Carlucci, P., De Paulis, A., and Mormile, I. (2025). Development and implementation of Phleos, a web-based tool for the data collection on Hypereosinophilic syndrome: The Italian Network on HES (INHES) study protocol. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1638798"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1111\/all.14690","article-title":"EAACI Biologicals Guidelines\u2014Dupilumab for children and adults with moderate-to-severe atopic dermatitis","volume":"76","author":"Agache","year":"2021","journal-title":"Allergy"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"D\u2019Aiuto, V., Mormile, I., Granata, F., Romano, A., Della Casa, F., Mignogna, G., de Paulis, A., and Rossi, F.W. (2025). Eosinophil-Driven vs. Eosinophil-Associated Severe Asthma: Practical Implications for Target Treatment. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26041729"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1111\/all.14809","article-title":"Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: A systematic review for the EAACI guidelines","volume":"76","author":"Agache","year":"2021","journal-title":"Allergy"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s12931-021-01775-z","article-title":"Real-life evidence of low-dose mepolizumab efficacy in EGPA: A case series","volume":"22","author":"Detoraki","year":"2021","journal-title":"Respir. Res."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Al-Azzawi, H.M.A., Paolini, R., Cirillo, N., O\u2019Reilly, L.A., Mormile, I., Moore, C., Yap, T., and Celentano, A. (2024). Eosinophils in Oral Disease: A Narrative Review. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25084373"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Mormile, I., Petraroli, A., Loffredo, S., Rossi, F.W., Mormile, M., Del Mastro, A., Spadaro, G., de Paulis, A., and Bova, M. (2021). Episodic Angioedema with Hypereosinophilia (Gleich\u2019s Syndrome): A Case Report and Extensive Review of the Literature. J. Clin. Med., 10.","DOI":"10.3390\/jcm10071442"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1001\/jamadermatol.2025.1578","article-title":"Psoriasis Risk in Patients with Atopic Dermatitis Treated with Dupilumab","volume":"161","author":"Lin","year":"2025","journal-title":"JAMA Dermatol."},{"key":"ref_47","first-page":"e81636","article-title":"Dupilumab-Induced Psoriasis in a Patient with Prurigo Nodularis: A Case Report","volume":"17","author":"Ogawa","year":"2025","journal-title":"Cureus"},{"key":"ref_48","first-page":"1458","article-title":"Generalized pustular psoriasis in a patient with asthma following dupilumab and tezepelumab therapy","volume":"23","author":"Kawakami","year":"2025","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1073\/pnas.1416922112","article-title":"IL-4 abrogates T(H)17 cell-mediated inflammation by selective silencing of IL-23 in antigen-presenting cells","volume":"112","author":"Guenova","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1093\/rheumatology\/keaa568","article-title":"Regulation of entheseal IL-23 expression by IL-4 and IL-13 as an explanation for arthropathy development under dupilumab therapy","volume":"60","author":"Bridgewood","year":"2021","journal-title":"Rheumatology"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/bjd.19459","article-title":"Increased expression of interleukin-23A in lesional skin of patients with atopic dermatitis with psoriasiform reaction during dupilumab treatment","volume":"184","author":"Napolitano","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/bjd.20064","article-title":"Dupilumab-induced phenotype switch from atopic dermatitis to psoriasis is characterized by de novo interleukin-17A expression: A case report","volume":"185","author":"Mirza","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1016\/j.jaad.2021.06.893","article-title":"Comment on: Development of psoriasis during treatment with dupilumab: A systematic review","volume":"86","author":"Cohen","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/nm804","article-title":"Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease","volume":"9","author":"Ghoreschi","year":"2003","journal-title":"Nat. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e316","DOI":"10.1111\/1346-8138.15472","article-title":"Unexpected side-effect of dupilumab: Reversal of hair graying","volume":"47","author":"Sumitomo","year":"2020","journal-title":"J. Dermatol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/jid.2012.331","article-title":"IL-4 inhibits the melanogenesis of normal human melanocytes through the JAK2-STAT6 signaling pathway","volume":"133","author":"Choi","year":"2013","journal-title":"J. Invest. Dermatol."},{"key":"ref_57","first-page":"e41","article-title":"Dermatitis and alopecia in a patient treated with dupilumab: A new adverse effect?","volume":"44","author":"Suarez","year":"2019","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41533-023-00330-1","article-title":"Key recommendations for primary care from the 2022 Global Initiative for Asthma (GINA) update","volume":"33","author":"Levy","year":"2023","journal-title":"npj Prim. Care Respir. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.anai.2022.02.021","article-title":"Allergic and eosinophilic asthma in the era of biomarkers and biologics: Similarities, differences and misconceptions","volume":"129","author":"Oppenheimer","year":"2022","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4193\/Rhin20.401","article-title":"European Position Paper on Rhinosinusitis and Nasal Polyps 2020","volume":"58","author":"Fokkens","year":"2020","journal-title":"Rhinology"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/s41584-023-00958-w","article-title":"Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis","volume":"19","author":"Emmi","year":"2023","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1080\/02770903.2019.1708098","article-title":"The influence of self-assessment of asthma control on the Asthma Control Test outcome","volume":"58","author":"Przybyszowski","year":"2021","journal-title":"J. Asthma"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jaci.2006.08.042","article-title":"Reliability and predictive validity of the Asthma Control Test administered by telephone calls using speech recognition technology","volume":"119","author":"Schatz","year":"2007","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"113","DOI":"10.14639\/0392-100X-N0364","article-title":"Prognostic value of the Sinonasal Outcome Test 22 (SNOT-22) in chronic rhinosinusitis","volume":"40","author":"Gallo","year":"2020","journal-title":"Acta Otorhinolaryngol. Ital."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s00405-020-06266-3","article-title":"Chemosensory dysfunction in COVID-19 out-patients","volume":"278","author":"Villarreal","year":"2021","journal-title":"Eur. Arch. Otorhinolaryngol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"918","DOI":"10.21873\/invivo.12781","article-title":"Self-reported Smell and Taste Disorders in Patients with COVID-19: A Japanese Single-center Study","volume":"36","author":"Yamamoto","year":"2022","journal-title":"In Vivo"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"346","DOI":"10.18176\/jiaci.0595","article-title":"Smell and Taste Dysfunction in COVID-19 Is Associated with Younger Age in Ambulatory Settings: A Multicenter Cross-Sectional Study","volume":"30","author":"Villarreal","year":"2020","journal-title":"J. Investig. Allergol. Clin. Immunol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1093\/chemse\/bjaa066","article-title":"Gaining Back What Is Lost: Recovering the Sense of Smell in Mild to Moderate Patients After COVID-19","volume":"45","author":"Iannuzzi","year":"2020","journal-title":"Chem. Senses"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1034\/j.1600-0625.2001.100102.x","article-title":"The eczema area and severity index (EASI): Assessment of reliability in atopic dermatitis","volume":"10","author":"Hanifin","year":"2001","journal-title":"EASI Evaluator Group. Exp. Dermatol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/ajh.26352","article-title":"World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Shomali","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jaci.2022.10.026","article-title":"The Joint Task Force on Practice Parameters GRADE guidelines for the medical management of chronic rhinosinusitis with nasal polyposis","volume":"151","author":"Rank","year":"2023","journal-title":"J. Allergy Clin. Immunol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/4\/1525\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T18:18:32Z","timestamp":1771438712000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/4\/1525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,14]]},"references-count":71,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["jcm15041525"],"URL":"https:\/\/doi.org\/10.3390\/jcm15041525","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,14]]}}}